Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 221

1.

Molecular profiling of radical prostatectomy tissue from patients with no sign of progression identifies ERG as the strongest independent predictor of recurrence.

Yan W, Jamal M, Tan SH, Song Y, Young D, Chen Y, Katta S, Ying K, Ravindranath L, Woodle T, Kohaar I, Cullen J, Kagan J, Srivastava S, Dobi A, McLeod DG, Rosner IL, Sesterhenn IA, Srinivasan A, Srivastava S, Petrovics G.

Oncotarget. 2019 Nov 5;10(60):6466-6483. doi: 10.18632/oncotarget.27294. eCollection 2019 Nov 5.

2.

Unusual Suspect: A Case Report of Tubulocystic Renal Cell Carcinoma with Features of Cystic Renal Oncocytoma.

McFadden JD, Sesterhenn IA, Kern SQ.

Case Rep Urol. 2019 Aug 5;2019:2919686. doi: 10.1155/2019/2919686. eCollection 2019.

3.

ERG Tumor Type is Less Frequent in High Grade and High Stage Prostate Cancers of Chinese Men.

Baohong J, Sedarsky J, Srivastava S, Sesterhenn I, Dobi A, Quanlin L.

J Cancer. 2019 May 12;10(9):1991-1996. doi: 10.7150/jca.30025. eCollection 2019.

4.

Increased frequency of germline BRCA2 mutations associates with prostate cancer metastasis in a racially diverse patient population.

Petrovics G, Price DK, Lou H, Chen Y, Garland L, Bass S, Jones K, Kohaar I, Ali A, Ravindranath L, Young D, Cullen J, Dorsey TH, Sesterhenn IA, Brassell SA, Rosner IL, Ross D, Dahut W, Ambs S, Figg WD, Srivastava S, Dean M.

Prostate Cancer Prostatic Dis. 2019 Sep;22(3):406-410. doi: 10.1038/s41391-018-0114-1. Epub 2018 Dec 12.

5.

John Shaw Billings and American military medical history.

Lewin-Smith MR, Sesterhenn IA.

J R Soc Med. 2018 Oct;111(10):344. doi: 10.1177/0141076818783325. No abstract available.

PMID:
30319003
6.

Circulating and intraprostatic sex steroid hormonal profiles in relation to male pattern baldness and chest hair density among men diagnosed with localized prostate cancers.

Zhou CK, Stanczyk FZ, Hafi M, Veneroso CC, Lynch B, Falk RT, Niwa S, Emanuel E, Gao YT, Hemstreet GP, Zolfghari L, Carroll PR, Manyak MJ, Sesterhenn IA, Levine PH, Hsing AW, Cook MB.

Prostate. 2017 Dec;77(16):1573-1582. doi: 10.1002/pros.23433. Epub 2017 Oct 2.

7.

Erratum: ETS Related Gene mediated Androgen Receptor Aggregation and Endoplasmic Reticulum Stress in Prostate Cancer Development.

Sreenath TL, Macalindong SS, Mikhalkevich N, Sharad S, Mohamed A, Young D, Borbiev T, Xavier C, Gupta R, Jamal M, Babcock K, Tan SH, Nevalainen MT, Dobi A, Petrovics G, Sesterhenn IA, Rosner IL, Bieberich CJ, Nelson P, Vasioukhin V, Srivastava S.

Sci Rep. 2017 Sep 6;7(1):10693. doi: 10.1038/s41598-017-09612-4.

8.

Predicting Prostate Cancer Progression as a Function of ETS-related Gene Status, Race, and Obesity in a Longitudinal Patient Cohort.

Cullen J, Young D, Chen Y, Degon M, Farrell J, Sedarsky J, Baptiste W, Rosen P, Tolstikov V, Kiebish M, Kagan J, Srivastava S, Kuo HC, Moncur JT, Rosner IL, Narain N, Akmaev V, Petrovics G, Dobi A, McLeod DG, Srivastava S, Sesterhenn IA.

Eur Urol Focus. 2018 Dec;4(6):818-824. doi: 10.1016/j.euf.2017.02.016. Epub 2017 Mar 11.

PMID:
28753864
9.

TMPRSS2:ERG Gene Fusions in Prostate Cancer of West African Men and a Meta-Analysis of Racial Differences.

Zhou CK, Young D, Yeboah ED, Coburn SB, Tettey Y, Biritwum RB, Adjei AA, Tay E, Niwa S, Truelove A, Welsh J, Mensah JE, Hoover RN, Sesterhenn IA, Hsing AW, Srivastava S, Cook MB.

Am J Epidemiol. 2017 Dec 15;186(12):1352-1361. doi: 10.1093/aje/kwx235. Review.

10.

Testicular Seminoma and Its Mimics: From the Radiologic Pathology Archives.

Marko J, Wolfman DJ, Aubin AL, Sesterhenn IA.

Radiographics. 2017 Jul-Aug;37(4):1085-1098. doi: 10.1148/rg.2017160164. Epub 2017 Jun 2. Review.

11.

ETS Related Gene mediated Androgen Receptor Aggregation and Endoplasmic Reticulum Stress in Prostate Cancer Development.

Sreenath TL, Macalindong SS, Mikhalkevich N, Sharad S, Mohamed A, Young D, Borbiev T, Xavier C, Gupta R, Jamal M, Babcock K, Tan SH, Nevalainen MT, Dobi A, Petrovics G, Sesterhenn IA, Rosner IL, Bieberich CJ, Nelson P, Vasioukhin V, Srivastava S.

Sci Rep. 2017 Apr 24;7(1):1109. doi: 10.1038/s41598-017-01187-4. Erratum in: Sci Rep. 2017 Sep 6;7(1):10693.

12.

Autoantibodies against oncogenic ERG protein in prostate cancer: potential use in diagnosis and prognosis in a panel with C-MYC, AMACR and HERV-K Gag.

Rastogi A, Ali A, Tan SH, Banerjee S, Chen Y, Cullen J, Xavier CP, Mohamed AA, Ravindranath L, Srivastav J, Young D, Sesterhenn IA, Kagan J, Srivastava S, McLeod DG, Rosner IL, Petrovics G, Dobi A, Srivastava S, Srinivasan A.

Genes Cancer. 2016 Nov;7(11-12):394-413. doi: 10.18632/genesandcancer.126.

13.

A novel genomic alteration of LSAMP associates with aggressive prostate cancer in African American men.

Petrovics G, Li H, Stümpel T, Tan SH, Young D, Katta S, Li Q, Ying K, Klocke B, Ravindranath L, Kohaar I, Chen Y, Ribli D, Grote K, Zou H, Cheng J, Dalgard CL, Zhang S, Csabai I, Kagan J, Takeda D, Loda M, Srivastava S, Scherf M, Seifert M, Gaiser T, McLeod DG, Szallasi Z, Ebner R, Werner T, Sesterhenn IA, Freedman M, Dobi A, Srivastava S.

EBioMedicine. 2015 Oct 31;2(12):1957-64. doi: 10.1016/j.ebiom.2015.10.028. eCollection 2015 Dec.

14.

Patient-specific Meta-analysis of 2 Clinical Validation Studies to Predict Pathologic Outcomes in Prostate Cancer Using the 17-Gene Genomic Prostate Score.

Brand TC, Zhang N, Crager MR, Maddala T, Dee A, Sesterhenn IA, Simko JP, Cooperberg MR, Srivastava S, Rosner IL, Chan JM, Febbo PG, Carroll PR, Cullen J, Lawrence HJ.

Urology. 2016 Mar;89:69-75. doi: 10.1016/j.urology.2015.12.008. Epub 2015 Dec 23.

15.

Mesenchymal Extratesticular Tumors and Tumorlike Conditions: From the Radiologic Pathology Archives.

Wolfman DJ, Marko J, Gould CF, Sesterhenn IA, Lattin GE Jr.

Radiographics. 2015 Nov-Dec;35(7):1943-54. doi: 10.1148/rg.2015150179. Epub 2015 Oct 30. Review.

PMID:
26517315
16.

Silencing of PMEPA1 accelerates the growth of prostate cancer cells through AR, NEDD4 and PTEN.

Li H, Mohamed AA, Sharad S, Umeda E, Song Y, Young D, Petrovics G, McLeod DG, Sesterhenn IA, Sreenath T, Dobi A, Srivastava S.

Oncotarget. 2015 Jun 20;6(17):15137-49.

17.

Prostate cancer marker panel with single cell sensitivity in urine.

Nickens KP, Ali A, Scoggin T, Tan SH, Ravindranath L, McLeod DG, Dobi A, Tacha D, Sesterhenn IA, Srivastava S, Petrovics G.

Prostate. 2015 Jun 15;75(9):969-75. doi: 10.1002/pros.22981. Epub 2015 Mar 23.

18.

ERG oncoprotein expression in prostate carcinoma patients of different ethnicities.

Kelly GM, Kong YH, Dobi A, Srivastava S, Sesterhenn IA, Pathmanathan R, Tan HM, Tan SH, Cheong SC.

Mol Clin Oncol. 2015 Jan;3(1):23-30. Epub 2014 Sep 18.

19.

A Biopsy-based 17-gene Genomic Prostate Score Predicts Recurrence After Radical Prostatectomy and Adverse Surgical Pathology in a Racially Diverse Population of Men with Clinically Low- and Intermediate-risk Prostate Cancer.

Cullen J, Rosner IL, Brand TC, Zhang N, Tsiatis AC, Moncur J, Ali A, Chen Y, Knezevic D, Maddala T, Lawrence HJ, Febbo PG, Srivastava S, Sesterhenn IA, McLeod DG.

Eur Urol. 2015 Jul;68(1):123-31. doi: 10.1016/j.eururo.2014.11.030. Epub 2014 Nov 29.

20.

ERG oncoprotein inhibits ANXA2 expression and function in prostate cancer.

Griner NB, Young D, Chaudhary P, Mohamed AA, Huang W, Chen Y, Sreenath T, Dobi A, Petrovics G, Vishwanatha JK, Sesterhenn IA, Srivastava S, Tan SH.

Mol Cancer Res. 2015 Feb;13(2):368-79. doi: 10.1158/1541-7786.MCR-14-0275-T. Epub 2014 Oct 24.

21.

Predominance of ERG-negative high-grade prostate cancers in African American men.

Farrell J, Young D, Chen Y, Cullen J, Rosner IL, Kagan J, Srivastava S, McLEOD DG, Sesterhenn IA, Srivastava S, Petrovics G.

Mol Clin Oncol. 2014 Nov;2(6):982-986. Epub 2014 Aug 7.

22.

Functional antagonism of TMPRSS2-ERG splice variants in prostate cancer.

Rastogi A, Tan SH, Mohamed AA, Chen Y, Hu Y, Petrovics G, Sreenath T, Kagan J, Srivastava S, McLeod DG, Sesterhenn IA, Srivastava S, Dobi A, Srinivasan A.

Genes Cancer. 2014 Jul;5(7-8):273-84.

23.

Legends in urology.

Sesterhenn I, Mostofi FK.

Can J Urol. 2014 Jun;21(3):7256-8. No abstract available.

24.

Increased association of the ERG oncoprotein expression in advanced stages of prostate cancer in Filipinos.

Raymundo EM, Diwa MH, Lapitan MC, Plaza AB, Sevilleja JE, Srivastava S, Sesterhenn IA.

Prostate. 2014 Aug;74(11):1079-85. doi: 10.1002/pros.22791. Epub 2014 Jun 9.

PMID:
24909781
25.

Methylation of the PMEPA1 gene, a negative regulator of the androgen receptor in prostate cancer.

Sharad S, Ravindranath L, Haffner MC, Li H, Yan W, Sesterhenn IA, Chen Y, Ali A, Srinivasan A, McLeod DG, Yegnasubramanian S, Srivastava S, Dobi A, Petrovics G.

Epigenetics. 2014 Jun;9(6):918-27. doi: 10.4161/epi.28710. Epub 2014 Apr 2.

26.

ERG rearrangement and protein expression in the progression to castration-resistant prostate cancer.

Gsponer JR, Braun M, Scheble VJ, Zellweger T, Bachmann A, Perner S, Vlajnic T, Srivastava M, Tan SH, Dobi A, Sesterhenn IA, Srivastava S, Bubendorf L, Ruiz C.

Prostate Cancer Prostatic Dis. 2014 Jun;17(2):126-31. doi: 10.1038/pcan.2013.62. Epub 2014 Jan 28.

27.

Diagnostic criteria for ductal adenocarcinoma of the prostate: interobserver variability among 20 expert uropathologists.

Seipel AH, Delahunt B, Samaratunga H, Amin M, Barton J, Berney DM, Billis A, Cheng L, Comperat E, Evans A, Fine SW, Grignon D, Humphrey PA, Magi-Galluzzi C, Montironi R, Sesterhenn I, Srigley JR, Trpkov K, van der Kwast T, Varma M, Zhou M, Ahmad A, Moss S, Egevad L.

Histopathology. 2014 Aug;65(2):216-27. doi: 10.1111/his.12382. Epub 2014 Apr 3.

PMID:
24467262
28.

Anterior tumors of the prostate: clinicopathological features and outcomes.

Mygatt J, Sesterhenn I, Rosner I, Chen Y, Cullen J, Morris-Gore T, Barton J, Dobi A, Srivastava S, McLeod D, Brassell SA.

Prostate Cancer Prostatic Dis. 2014 Mar;17(1):75-80. doi: 10.1038/pcan.2013.54. Epub 2013 Dec 3.

PMID:
24296774
29.

Evaluation of ERG responsive proteome in prostate cancer.

Tan SH, Furusato B, Fang X, He F, Mohamed AA, Griner NB, Sood K, Saxena S, Katta S, Young D, Chen Y, Sreenath T, Petrovics G, Dobi A, McLeod DG, Sesterhenn IA, Saxena S, Srivastava S.

Prostate. 2014 Jan;74(1):70-89. doi: 10.1002/pros.22731. Epub 2013 Sep 21.

30.

Low Frequency of the ERG Oncogene Alterations in Prostate Cancer Patients from India.

Rawal S, Young D, Williams M, Colombo M, Krishnappa R, Petrovics G, McLeod DG, Srivastava S, Sesterhenn IA.

J Cancer. 2013 Jul 5;4(6):468-72. doi: 10.7150/jca.6568. Print 2013.

31.

N-cadherin Expression in Testicular Germ Cell and Gonadal Stromal Tumors.

Heidenberg DJ, Barton JH, Young D, Grinkemeyer M, Sesterhenn IA.

J Cancer. 2012;3:381-9. doi: 10.7150/jca.5017. Epub 2012 Sep 11.

32.

Differences in frequency of ERG oncoprotein expression between index tumors of Caucasian and African American patients with prostate cancer.

Rosen P, Pfister D, Young D, Petrovics G, Chen Y, Cullen J, Böhm D, Perner S, Dobi A, McLeod DG, Sesterhenn IA, Srivastava S.

Urology. 2012 Oct;80(4):749-53. doi: 10.1016/j.urology.2012.07.001. Epub 2012 Aug 28.

33.

Elevated osteonectin/SPARC expression in primary prostate cancer predicts metastatic progression.

Derosa CA, Furusato B, Shaheduzzaman S, Srikantan V, Wang Z, Chen Y, Seifert M, Ravindranath L, Young D, Nau M, Dobi A, Werner T, McLeod DG, Vahey MT, Sesterhenn IA, Srivastava S, Petrovics G.

Prostate Cancer Prostatic Dis. 2012 Jun;15(2):150-6. doi: 10.1038/pcan.2011.61. Epub 2011 Nov 29. Erratum in: Prostate Cancer Prostatic Dis. 2012 Jun;15(2):210. Siefert, M [corrected to Seifert, M].

PMID:
22343836
34.

Clinical potential of the ERG oncoprotein in prostate cancer.

Rosen P, Sesterhenn IA, Brassell SA, McLeod DG, Srivastava S, Dobi A.

Nat Rev Urol. 2012 Feb 14;9(3):131-7. doi: 10.1038/nrurol.2012.10. Review.

PMID:
22331093
35.

ERG transcription factor as an immunohistochemical marker for vascular endothelial tumors and prostatic carcinoma.

Miettinen M, Wang ZF, Paetau A, Tan SH, Dobi A, Srivastava S, Sesterhenn I.

Am J Surg Pathol. 2011 Mar;35(3):432-41. doi: 10.1097/PAS.0b013e318206b67b.

36.

ERG oncogene modulates prostaglandin signaling in prostate cancer cells.

Mohamed AA, Tan SH, Sun C, Shaheduzzaman S, Hu Y, Petrovics G, Chen Y, Sesterhenn IA, Li H, Sreenath T, McLeod DG, Dobi A, Srivastava S.

Cancer Biol Ther. 2011 Feb 15;11(4):410-7. Epub 2011 Feb 15.

37.

Targeted disruption of Ing2 results in defective spermatogenesis and development of soft-tissue sarcomas.

Saito M, Kumamoto K, Robles AI, Horikawa I, Furusato B, Okamura S, Goto A, Yamashita T, Nagashima M, Lee TL, Baxendale VJ, Rennert OM, Takenoshita S, Yokota J, Sesterhenn IA, Trivers GE, Hussain SP, Harris CC.

PLoS One. 2010 Nov 19;5(11):e15541. doi: 10.1371/journal.pone.0015541.

38.

Ets family protein, erg expression in developing and adult mouse tissues by a highly specific monoclonal antibody.

Mohamed AA, Tan SH, Mikhalkevich N, Ponniah S, Vasioukhin V, Bieberich CJ, Sesterhenn IA, Dobi A, Srivastava S, Sreenath TL.

J Cancer. 2010 Oct 25;1:197-208.

39.

Assessment of circulating tumor cells (CTCs) in prostate cancer patients with low-volume tumors.

Ali A, Furusato B, Ts'o PO, Lum ZP, Elsamanoudi S, Mohamed A, Srivastava S, Moul JW, Brassell SA, Sesterhenn IA, McLeod DG.

Pathol Int. 2010 Oct;60(10):667-72. doi: 10.1111/j.1440-1827.2010.02584.x.

PMID:
20846264
40.

Overexpression of C-MYC oncogene in prostate cancer predicts biochemical recurrence.

Hawksworth D, Ravindranath L, Chen Y, Furusato B, Sesterhenn IA, McLeod DG, Srivastava S, Petrovics G.

Prostate Cancer Prostatic Dis. 2010 Dec;13(4):311-5. doi: 10.1038/pcan.2010.31. Epub 2010 Sep 7.

PMID:
20820186
41.

ERG oncoprotein expression in prostate cancer: clonal progression of ERG-positive tumor cells and potential for ERG-based stratification.

Furusato B, Tan SH, Young D, Dobi A, Sun C, Mohamed AA, Thangapazham R, Chen Y, McMaster G, Sreenath T, Petrovics G, McLeod DG, Srivastava S, Sesterhenn IA.

Prostate Cancer Prostatic Dis. 2010 Sep;13(3):228-37. doi: 10.1038/pcan.2010.23. Epub 2010 Jun 29.

42.

Ocular perivascular epithelioid cell tumor: report of 2 cases with distinct clinical presentations.

Furusato E, Cameron JD, Newsom RW, Fujishiro T, Kojima T, Specht CS, Fetsch JF, Furusato B, Sesterhenn IA, Rushing EJ.

Hum Pathol. 2010 May;41(5):768-72. doi: 10.1016/j.humpath.2009.12.006. Epub 2010 Mar 17.

PMID:
20236689
43.

Evaluation of the ETS-related gene mRNA in urine for the detection of prostate cancer.

Rice KR, Chen Y, Ali A, Whitman EJ, Blase A, Ibrahim M, Elsamanoudi S, Brassell S, Furusato B, Stingle N, Sesterhenn IA, Petrovics G, Miick S, Rittenhouse H, Groskopf J, McLeod DG, Srivastava S.

Clin Cancer Res. 2010 Mar 1;16(5):1572-6. doi: 10.1158/1078-0432.CCR-09-2191. Epub 2010 Feb 16.

44.

Prostate cancer risk allele specific for African descent associates with pathologic stage at prostatectomy.

Whitman EJ, Pomerantz M, Chen Y, Chamberlin MM, Furusato B, Gao C, Ali A, Ravindranath L, Dobi A, Sesterhenn IA, McLeod DG, Srivastava S, Freedman M, Petrovics G.

Cancer Epidemiol Biomarkers Prev. 2010 Jan;19(1):1-8. doi: 10.1158/1055-9965.EPI-08-1111. Erratum in: Cancer Epidemiol Biomarkers Prev. 2010 Mar;19(3):890. Sestrehenn, Isabell A [corrected to Sesterhenn, Isabell A].

45.

Osteoblast-specific factor 2 expression in prostate cancer-associated stroma: identification through microarray technology.

Furusato B, Tsunoda T, Shaheduzzaman S, Nau ME, Vahey M, Petrovics G, McLeod DG, Naito S, Shirasawa S, Srivastava S, Sesterhenn IA.

Urology. 2010 Apr;75(4):768-72. doi: 10.1016/j.urology.2009.10.026. Epub 2009 Dec 29.

PMID:
20035976
46.

Clinicopathological behavior of single focus prostate adenocarcinoma.

Rice KR, Furusato B, Chen Y, McLeod DG, Sesterhenn IA, Brassell SA.

J Urol. 2009 Dec;182(6):2689-94. doi: 10.1016/j.juro.2009.08.055.

PMID:
19836800
47.

Quantitative expression of TMPRSS2 transcript in prostate tumor cells reflects TMPRSS2-ERG fusion status.

Mwamukonda K, Chen Y, Ravindranath L, Furusato B, Hu Y, Sterbis J, Osborn D, Rosner I, Sesterhenn IA, McLeod DG, Srivastava S, Petrovics G.

Prostate Cancer Prostatic Dis. 2010 Mar;13(1):47-51. doi: 10.1038/pcan.2009.28. Epub 2009 Jul 14.

48.

The increased expression of periostin during early stages of prostate cancer and advanced stages of cancer stroma.

Tsunoda T, Furusato B, Takashima Y, Ravulapalli S, Dobi A, Srivastava S, McLeod DG, Sesterhenn IA, Ornstein DK, Shirasawa S.

Prostate. 2009 Sep 15;69(13):1398-403. doi: 10.1002/pros.20988.

PMID:
19479898
49.

PCA3 score before radical prostatectomy predicts extracapsular extension and tumor volume.

Whitman EJ, Groskopf J, Ali A, Chen Y, Blase A, Furusato B, Petrovics G, Ibrahim M, Elsamanoudi S, Cullen J, Sesterhenn IA, Brassell S, Rittenhouse H, Srivastava S, McLeod DG.

J Urol. 2008 Nov;180(5):1975-8; discussion 1978-9. doi: 10.1016/j.juro.2008.07.060. Epub 2008 Sep 17.

PMID:
18801539
50.

Glassy cell carcinoma of the urethra.

Weissbart SJ, Bianco FJ Jr, Sotelo T, Atalla MA, Sesterhenn IA, Jarrett TW.

Urology. 2009 Jan;73(1):60. doi: 10.1016/j.urology.2008.06.033. Epub 2008 Aug 13.

PMID:
18701143

Supplemental Content

Loading ...
Support Center